The treatment landscape for ATTR amyloidosis is changing. And clinicians can potentially look forward to having more treatment options for their patients through ongoing studies that use strategies for reducing the production of transthyretin (TTR) protein. To hear more, join Dr. Marianna Fontana, Director of the UCL CMR unit at the Royal Free Hospital. She is Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, UK.
Transformation of Treatment Strategies for ATTR Amyloidosis

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
The treatment landscape for ATTR amyloidosis is changing. And clinicians can potentially look forward to having more treatment options for their patients through ongoing studies that use strategies for reducing the production of transthyretin (TTR) protein. To hear more, join Dr. Marianna Fontana, Director of the UCL CMR unit at the Royal Free Hospital. She is Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, UK.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
Updates From the 7th World Symposium Task Force
Chemotherapy Strategies for Metastatic PDAC
TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
A Practical Guide to Prescribing in HF
Clinical Conundrums in ARIA: Nuances of Microhemorrhages when Evaluating an MRI for ARIA
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?